MARKET

IMUX

IMUX

Immunic Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.22
-0.40
-4.59%
Closed 16:00 01/24 EST
OPEN
8.79
PREV CLOSE
8.61
HIGH
8.93
LOW
8.15
VOLUME
25.05K
TURNOVER
--
52 WEEK HIGH
46.80
52 WEEK LOW
6.20
MARKET CAP
83.11M
P/E (TTM)
-1.5664
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of IMUX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

IMUX News

  • Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.
  • PR Newswire.01/08 11:30
  • Immunic, Inc. to Present Data on IMU-856, for the First Time, at the Crohn's and Colitis Foundation's IBD Innovate Conference
  • PR Newswire.12/04/2019 11:30
  • Immunic, Inc. to Participate in Investor and Scientific Conferences in December
  • PR Newswire.11/25/2019 11:30
  • Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips
  • PR Newswire.11/19/2019 11:30

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About IMUX

Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.
More

Webull offers Immunic Inc (IMUX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.